Strong drug trial results powered biotech gains, while margin pressure in transport and a major earnings miss in the freelance platform space weighed on other names.

Rare Strategy (Sponsored)
It wasn't stocks. It wasn't real estate.
It was a little-known investment vehicle that turned Mitt Romney's $450,000 into as much as $100 million and Peter Thiel used to turn $2,000 into $5 billion within two decades.
Now, thanks to a new executive order, regular Americans can access the same type of investment.
Get more details here

Markets
Wall Street was undecided as investors rotated during a busy earnings session, taking profits in tech while rewarding stronger reports elsewhere. Softer retail sales pushed Treasury yields lower, helping blue chips but weighing on growth names, leaving the Dow up and the Nasdaq down.
DJIA [+0.10%]
S&P 500 [-0.33%]
Nasdaq [-0.59%]
Russell 2k [-0.14%]

Market-Moving News
Cybersecurity
Why Google's Largest Acquisition Ever Is a Defense Play

Alphabet Inc (NASDAQ: GOOGL) just cleared the final major regulatory hurdle for its $32 billion acquisition of Wiz, the largest deal the company has ever made. The EU approved it unconditionally, confirming that the acquisition does not raise competition concerns.
When a deal this size sails through without conditions, it tells you the strategic logic was hard to argue against. Google is making a massive structural move to reshape how it competes in cloud computing, where it has been running third for years.
Cloud Needs a Security Story
Google has the infrastructure and the AI talent, but cybersecurity has become the feature that enterprise clients evaluate before everything else. Wiz brings exactly that, a cloud security platform that has grown at an extraordinary pace and already sits inside some of the largest organizations in the world.
Bolting that capability directly into Google Cloud changes the pitch. Instead of selling compute and storage, Google now walks into your enterprise conversation with security baked in from the start.
Third Place Just Got More Dangerous
Running behind in the cloud has been Google's most visible competitive gap for years. This acquisition does not close that gap overnight, but it changes the trajectory.
When the number three player spends $32 billion to add the hottest cybersecurity platform on the market, you stop thinking about the ranking and start paying attention to the momentum.

Banking
Cards, Cars, and a Bank That Feels Uncaged

Wells Fargo (NYSE: WFC) is projecting loan growth across its consumer business in 2026, with credit cards and auto lending leading the charge. This is the first full year without the $1.95 trillion asset cap the Federal Reserve imposed after the fake accounts scandal, and the difference is already visible.
For years, Wells Fargo watched competitors grow while operating under a balance-sheet ceiling. That ceiling is gone now.
Cards Are Carrying the Momentum
Credit card growth has been consistent for several quarters, driven by newer products launched over the past few years. The bank is now pushing further with cards aimed at wealth management clients and segments it has not fully tapped yet.
When you see a bank this size building a card strategy around newer products rather than legacy portfolios, it signals a business purposefully rebuilding its revenue mix.
Auto Lending Finds Its Lane
The auto business returned to growth in 2025, driven by stronger originations and rising loan balances. Preferred financing partnerships with major automakers have added steady volume, and that momentum is expected to carry through this year.
Uncaged and Moving
This is a different Wells Fargo than the one stuck in damage control for the better part of a decade. The asset cap defined your perception of this bank for years, and now the constraint is gone.
If you have been waiting for the moment Wells Fargo shifts from cleanup to competition, this is what the early innings look like.

Pre-IPO Access (Sponsored)
This is time-sensitive.
James Altucher is explaining how everyday investors may be able to gain pre-IPO exposure to SpaceX—starting with just $100.
No special access.
No private deals.
Just a regular brokerage account.
James reveals the name and ticker symbol in a short, free video so you can decide if it’s right for you.
Watch the free video here

Healthcare Real Estate
$23 Billion Worth of Bets on Where America Gets Old

Welltower Inc (NYSE: WELL) just completed $23 billion in transactions to reshape the company completely. Buy $14 billion in premium senior housing, sell off a $7 billion outpatient medical portfolio, and come out the other side as a business that earns most of its income from one sector.
Senior housing now accounts for the mid-80s of operating income. That is not diversification. That is conviction.
The Demographic Math Is Loud
The oldest baby boomers turn 80 this year, and senior housing occupancy is projected to cross 90% for the first time in two decades. New supply is barely trickling in, sitting at its lowest level since 2006.
You do not need a spreadsheet to see what happens when demand surges and supply stays flat. Welltower timed this pivot to ride that wave directly.
One Direction, No Hedging
Most companies this size spread their bets. Welltower concentrated almost everything into senior housing at the exact moment the demographic tailwind picks up speed. Your read on that depends on how inevitable you think the aging wave really is.
Built to Operate, Not Just Own
Welltower sees itself as an operator wrapped in real estate. Twelve consecutive quarters of 20%-plus growth in its senior housing portfolio back that up.
When you stack operational momentum on top of a generational shift with almost no new competition being built, the setup stops looking like a bet and starts looking unavoidable.

Want to make sure you never miss our post-market roundup?
Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone right after the closing bell rings.
Email’s great. Texts are faster.

Top Winners and Losers
Evommune Inc [EVMN] $28.96 (+70.45%)
Evommune surged after reporting highly statistically significant Phase 2a results for its atopic dermatitis drug EVO301, demonstrating strong efficacy and a clean safety profile in moderate-to-severe patients.
Nektar Therapeutics [NKTR] $56.00 (+51.07%)
Nektar rallied after announcing positive long-term Phase 2b maintenance data for rezpegaldesleukin in atopic dermatitis, showing sustained disease control and deepening responses through one year.
Ichor Holdings Ltd [ICHR] $45.27 (+32.72%)
Ichor gained after posting a surprise quarterly profit and beating revenue estimates, while an improving earnings outlook prompted a favorable Zacks rating upgrade.

Proficient Auto Logistics Inc [PAL] $7.77 (-25.57%)
Proficient Auto Logistics fell after reporting a sharp swing to an operating loss driven by a $27.8M goodwill impairment, while margins weakened and revenue per unit declined in a tougher pricing environment.
Gilat Satellite Networks Ltd [GILT] $15.04 (-21.95%)
Gilat dropped despite a revenue beat as GAAP earnings declined year over year and operating profit lagged sales growth, raising concerns about margin pressure.
Upwork Inc [UPWK] $15.21 (-19.08%)
Upwork, an online work marketplace, slipped after missing earnings expectations by a wide margin, with profits falling sharply from a year ago despite a slight revenue beat.

Poll: Which product category do you think is MOST overpriced relative to cost?

AI Stocks to Watch (Sponsored)
The Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.
But the Man Who Called Nvidia at $1.10 Says "AI's Next Magnificent Seven Could Do It Even Faster."

Everything Else
Paramount just slid Warner Bros a sweeter deal, offering to cover the Netflix breakup tab and then some, because sometimes you gotta pay to play.
Kalshi says Super Bowl betting hit $1B in volume, turning America's biggest game into a live stress test for prediction markets.
Silver demand is holding steady through 2026 thanks to rising investment, proving the shiny metal still has believers even when gold steals the headlines.
U.S. stocks inched higher on earnings vibes, with the Dow stretching its record run past the 50,000 milestone like it's got nowhere else to be.
Novo Nordisk opened a second front in the weight-loss wars, suing Hims over Wegovy knockoffs like patent lawyers are the new blockbuster drug.

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!
Thanks for reading. I'll see you at the next open!
Best Regards,
— Adam G.
Elite Trade Club
Click here to get our daily newsletter straight to your cell for free.
P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.




